S2. Synthesis of sodium (2R,4S)-6-oxo-2-undecylhexahydropyrimidine-4-carboxylate (ALA-11):
To a solution of sodium hydroxide (1.0 mmol) in methanol (10 mL) was added L-asparagine (1.0 mmol) and the mixture was gently stirred for 15 min. To this clear solution, n-dodecanal (1.2 mmol) dissolved in methanol (10 mL) was added dropwise over 15 min and the mixture was stirred overnight at room temperature. The methanol was evaporated in vacuo and the residue was washed with hexane (325 mL), and upon drying, afforded ALA-11 (98%) as a white powder.   (500 MHz; D 2 O) 0.92 (3 H, t, J = 6.8, CH 3 ), m, 8 CH 2 ), 1.40-1.52 (2 H, m, CH 2 ), 1.67 (2 H, dt, J = 6.3, 7.7 Hz, CH 2 ), 2.32 (1 H, dd, J = 11.7, 17 .6, C(5)H ax ), 2.64 (1 H, dd, J = 4.9, 17.6, C(5)H eq ), 3.56 (1 H, dd, J = 4.9, 11.2, C(4)H ax ), 4.28 (1 H, t, J = 5.9, C(2)H ax ).  C (125 MHz; D 2 O; DSS): 16. 1, 24.9, 26.6, 31.9, 31.97, 32.04, 32.25, 32.26, 32.3, 34.3, 36.7, 37.6, 58.0, 69.0, 175.3, 180.3 . ATR-FTIR ( max , cm -1 ): 3309.6, 2915.1, 2847.7, 1671.4, 1638.9, 1599.7, 1468.3, 1391.0, 1336.0. S4. 13 C NMR of sodium (2R,4S)-6-oxo-2-undecylhexahydropyrimidine-4-carboxylate (ALA-11) in D 2 O containing sodium 4,4-dimethyl-4-silapentane-1-sulfonate (DSS).
S5. General procedure for self-assembly
To ensure the formation of uniform mixtures, different proportions of ALA-11 and cholesterol (mol ratios of cholesterol/ 10/90, 20/80, 30/70, 40/60, and 50/50 ; total moles of lipids: 1.26  10 -4 ) were dissolved in round bottom flasks using (50:50) methanol/chloroform. The solvent of each preparation was evaporated under reduced pressure to generate uniform thin films that were stored at 4 °C until needed. To assemble the nanocarriers, the cholesterol/ALA-11 thin film was hydrated with 4.0 mL of PBS (10 mM phosphate buffer, 137 mM NaCl, pH 7.4) and sequentially vortexed and incubated at 55-60 °C until all the material was suspended in the turbid dispersion. 
S7. Sample preparation for SEM and TEM studies
An aliquot of the suspension (100 L) obtained by the above protocol (section 1.3) was diluted with an equal volume of deionized water. The diluted samples were dispensed on 400-mesh copper grids coated with either lacey carbon or Formvar films, and the excess liquid was removed using a pointed filter paper. Three drops of uranyl acetate solution (2% wt/vol) were added to the copper grids, and again the excess fluids were removed with a pointed filter paper. The grids were air dried for 1 h before EM analysis. 
S8. Transmission electron micrographs (TEM

S9. Dynamic light scattering (DLS) measurements
Aliquots (200 L) of each of the dispersions of cholesterol/ALA-11 (0/100, 20/80, 40/60 mol%; 33 mM) were diluted in 1.8 mL of PBS (pH 7.4, 120 mM NaCl) and transferred to a disposable cell. Size determinations were carried out by Dynamic Light Scattering on the submicron particle size analyzer and counting was performed (20 accumulation times) at 25 °C using a deconvolution algorithm based on the CONTIN program. In these data collections, the measuring standard operating procedures were adjusted considering water as the medium for all experiments. Each experiment was performed using five independent runs.
S10. The zeta potential ( measurements
The zeta potentials were determined by measuring the electrophoretic mobilities under an applied 
S14. Sample preparation for encapsulation studies
To include a selected hydrophobic agent within the nanocarriers, the thin films were made using a homogeneous solution of cholesterol/ALA-11 containing the compound to be encapsulated in 50:50 methanol/chloroform. The thin films were processed as described above (section 1.3) into nanocarriers and unencapsulated (undissolved) material was removed by passage through 0.45 m filters or by Sephadex G-75 size exclusion chromatography. 2
S15. Encapsulation of protoporphyrin IX dimethyl ester (PPIX-Me 2 ) in cholesterol/ALA-11
Various vesicle formulations of cholesterol/ALA-11 (0/100, 20/80, and 40/60) containing 2 mol% protoporphyrin IX dimethyl ester (PPIX-Me 2 ) were made by the procedure described above (1.26 × 10 -4 moles of lipid and 2.52 × 10 -6 moles PPIX-Me 2 in 4 mL PBS). The mixtures were alternately vortexed and incubated at 60 °C. Each of incubated formulations was devided to two parts and one part was directly used to obtain the fluorescence spectra ( ex = 400 nm and  em = 630 nm) after it was diluted 1000-fold in methanol (dilution procedure: 10.0 L of each sample was made up to 10.0 mL with methanol). The known aliquots (600 L) of second part of each formulation were processed through 0.45 m filter or Sephadex G-75 column to remove non-encapsulated PPIX-Me 2 before the dilution with methanol and spectra were taken. The dilution in methanol was necessary to minimize the effect of light scattering and to dissolve the dye completely in methanol as well (the relavent spectra were illustrated in S16 and S17). The encapsulation efficiencies were estimated from the ratio of the aliquot fluorescence before and after filtration. The loading was calculated as mass of solute encapsulated per total mass of lipids used in the formulations. S16. Emission spectra of protoporphyrin dimethyl ester (PPIX-Me 2 ) when the non-encapsulated dye was removed by passage through 0.45 μm filter in S15, which were obtained by measuring the fluorescence at  ex = 412 nm (red: before PPIX-Me 2 removal; and black: after PPIX-Me 2 removal). The various mole ratios of cholesterol/ALA-11 used to study the association of PPIX-Me 2 with nanoparticles were: (a) 0/100; (b) 20/80; and (c) 40/60. S17. Emission spectra of protoporphyrin dimethyl ester (PPIX-Me 2 ) when the non-encapsulated dye was removed by Sephadex G-75 size exclusion in S15, which were obtained by measuring the 11 fluorescence at  ex = 412 nm (red: before PPIX-Me 2 removal; and black: after PPIX-Me 2 removal). The two mole ratios of cholesterol/ALA-11 used to study the association of PPIX-Me 2 with nanoparticles were: (a) 20/80 and (b) 40/60. S18. Stability of cholesterol/ALA-11 nanocarrier formulations after encapsulation of protoporphyrin IX dimethyl ester for two week period.
S19. Nile red encapsulation and controlled release under different pH conditions
Vesicle suspensions comprising cholesterol in ALA-11 (0 and 40 mol%) were prepared with Nile red (NR; 0.25 mol%) as the hydrophobic guest following the procedure described above. Aliquots of the respective suspensions (200 L) were diluted in a curvette with 3 mL of the media under studies (acetate buffer pH 5.0; phosphate buffer pH 6.0, 7.4). The samples were immediately transferred to the spectrofluorometer and timecourse fluorescence intensities were recorded ( ex = 400 nm and  em = 580, 600, or 630 nm, depending on the solvatochromic property of the dye in each environment under consideration). The percent NR retained in the nanoparticles was calculated using the formula,
where I t is the fluorescence at time (t), I o is the initial fluorescence of the sample and I f is the final fluorescence after complete degradation of the sample. The percentage of NR retained versus time (t) was plotted for the various formulations and pH (the graphical representation of the results was illustrated in Fig. 6 ).
S20
. The pH dependent degradation of ALA-11 and hence the aqeueous ALA-11 formulations Deuterated aqeueous formulation of ALA-11 in a deuterated phosphate buffer at pD 7.8 (pH 7.4; 33 mM) was prepared (1.26 × 10 -4 moles of lipid in 4 mL of buffer) and an aliquot of the solution (800 L) was diluted 50% with deuterated phosphate buffer at pD 7.8 (1:1 dilution). The 1 H NMR of this sample was immediately obtained and subsequent spectra were obtained as a function of time at 10 min intervals. The pH dependency of the ALA-11 formulations were tested by repeating this experiment at pH 5.0 and 6.0 using deuterated formulations of ALA-11 at pD 5.4 and 6.4, respectively. The percentages of the degradation were calculated from the changes in the integral values of representative peaks and they were then ploted against time as shown below (S21). 
